Indefinite- lived intangible impairment
Gilead Sciences Indefinite- lived intangible impairment decreased by 0.1% to $34.16B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.8%, from $34.77B to $34.16B. Over 5 years (FY 2020 to FY 2025), Indefinite- lived intangible impairment shows a downward trend with a -3.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase in impairment charges signals a decline in the value of the company's intangible assets, potentially indicating poor acquisition outcomes or changing market conditions.
Detailed definition
This represents the gross value of indefinite-lived intangible assets, excluding goodwill, that have been subject to imp...
Peer comparison
Varies significantly based on M&A history; companies with frequent acquisitions often show higher volatility in this metric.
other_intangible_assets_gross_excluding_goodwillHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $41.84B | $41.84B | $41.84B | $39.16B | $39.14B | $39.14B | $39.01B | $39.01B | $39.01B | $39.01B | $38.89B | $36.46B | $36.46B | $34.77B | $34.77B | $34.77B | $34.58B | $34.58B | $34.19B | $34.16B |
| QoQ Change | — | +0.0% | +0.0% | -6.4% | -0.0% | +0.0% | -0.3% | +0.0% | +0.0% | +0.0% | -0.3% | -6.2% | +0.0% | -4.6% | +0.0% | +0.0% | -0.5% | +0.0% | -1.1% | -0.1% |
| YoY Change | — | — | — | — | -6.4% | -6.4% | -6.7% | -0.4% | -0.3% | -0.3% | -0.3% | -6.5% | -6.5% | -10.9% | -10.6% | -4.6% | -5.1% | -0.5% | -1.7% | -1.8% |
Indefinite- lived intangible impairment at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's indefinite- lived intangible impairment?
- Gilead Sciences (GILD) reported indefinite- lived intangible impairment of $34.16B in Q1 2026.
- How has Gilead Sciences's indefinite- lived intangible impairment changed year-over-year?
- Gilead Sciences's indefinite- lived intangible impairment decreased by 1.8% year-over-year, from $34.77B to $34.16B.
- What is the long-term trend for Gilead Sciences's indefinite- lived intangible impairment?
- Over 5 years (2020 to 2025), Gilead Sciences's indefinite- lived intangible impairment has grown at a -3.0% compound annual growth rate (CAGR), from $39.79B to $34.19B.
- What does indefinite- lived intangible impairment mean?
- The total value of non-goodwill intangible assets that have been written down due to a loss in value.